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Abstract
Neuropsychiatric symptoms seen in Alzheimer’s disease (AD) are not simply a consequence of neurodegeneration, but probably result from
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differential neurotransmitter alterations, which some patients are more at risk of than others. Therefore, the hypothesis of this study is that
n imbalance between the cholinergic and serotonergic systems is related to cognitive symptoms and psychological syndromes of dementia
BPSD) in patients with AD. Cholinergic and serotonergic functions were assessed in post-mortem frontal and temporal cortex from 22 AD
atients who had been prospectively assessed with the Mini-Mental State examination (MMSE) for cognitive impairment and with the Present
ehavioral Examination (PBE) for BPSD including aggressive behavior, overactivity, depression and psychosis. Not only cholinergic deficits,
ut also the cholinacetyltransferase/serotonin ratio significantly correlated with final MMSE score both in frontal and temporal cortex. In
ddition, decreases in cholinergic function correlated with the aggressive behavior factor, supporting a dual role for the cholinergic system
n cognitive and non-cognitive disturbances associated to AD. The serotonergic system showed a significant correlation with overactivity
nd psychosis. The ratio of serotonin to acetylcholinesterase levels was also correlated with the psychotic factor at least in women. It is
oncluded that an imbalance between cholinergic–serotonergic systems may be responsible for the cognitive impairment associated to AD.
oreover, the major findings of this study are the relationships between neurochemical markers of both cholinergic and serotonergic systems
nd non-cognitive behavioral disturbances in patients with dementia.
2004 Elsevier Ltd. All rights reserved.
eywords: Cognitive decline; Behavioral and psychological syndromes of dementia (BPSD); Cholineacetyltransferase; 5-HT; Cortex; Human
. Introduction
Disruption of basal forebrain cholinergic pathways and
onsequent cortical cholinergic denervation is one of the hall-
arks of Alzheimer’s disease (AD), together with histopatho-
ogical changes such as neurofibrillary tangles and senile
laques. This cholinergic dysfunction in AD has been largely
elated to cognitive disturbances (Francis, Palmer, Snape, &
ilcock, 1999; Perry, Walker, Grace, & Perry, 1999). Besides
ognitive symptoms, most patients with AD suffer from be-
∗ Corresponding author. Tel.: +34 948 425 600; fax: +34 948 425 649.
E-mail address: mariaja@unav.es (M.J. Ramirez).
havioral and psychological syndromes of dementia (BPSD;
IPA, 1996), such as aggressive behavior, overactivity, de-
pression or psychosis (Hope, Keene, Fairburn, McShane,
& Jacoby, 1997) which are a major contributory factor to
early institutionalisation of the patients (Levy, Cummings,
& Kahn-Rose, 1999). Traditional treatments for BPSD are
antipsychotic medications, benzodiazepines or anticonvul-
sant medications, which are not devoid of serious adverse
effects, particularly in the elderly (Byerly et al., 2001). It is
therefore important to understand the neurochemical basis
of BPSD to allow the development of rational therapeutic
approaches. In this sense, observations in which cholinergic
replacement therapies resulted in behavioral improvements,
028-3932/$ – see front matter © 2004 Elsevier Ltd. All rights reserved.
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independent from effects on cognition, in patients with AD
(Paleacu, Mazeh, Mirecki, Even, & Barak, 2002) may have
important clinical implications. However, it is conceivable
that, due to the complexity and diversity of BPSD, more than
one transmitter system may contribute to a particular behav-
ioral syndrome; indeed, balance between pairs of neurotrans-
mitters may be of particular importance, e.g. both reduced
serotonergic and increased noradrenergic activities have
been linked to aggressive behavior (Lancot, Herrmann, &
Mazzota, 2001) and also a cholinergic–monoaminergic im-
balance has been postulated in the pathogenesis of affective
disorders (Cummings & Kaufer, 1996). Knowledge of im-
balances in these systems offers the opportunity for rational
treatment or prevention.
The involvement of the serotonergic system in higher cog-
nitive processes such as memory and learning has been well
described and there is evidence suggesting that changes in
this neurotransmitter system occur in association with non-
disease aging (Buhot, Martin, & Segu, 2000; Porter, Lunn,
& O’Brien, 2003). In animal studies, a combined blockade
of the cholinergic and serotonergic system contributes to a
severe and widespread deterioration of adaptative behavior,
condition that might be considered analogous to dementia in
man (Vanderwolf, 1987). In addition, while a selective re-
duction in cholinergic transmission often produces only mild
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degree of dementia (for review see Danysx & Parsons, 2003;
Francis, 2003).
In the present study, we have used clinical data and post-
mortem brains collected as part of a prospective community-
based study of behavior in dementia patients (Hope et al.,
1997) to test the hypothesis that an imbalance between the
cholinergic and serotonergic system contributes to both cog-
nitive deficits and BPSD in AD. We have studied the state
of the cholinergic and serotonergic neurotransmission in the
cerebral cortex with respect to cognitive impairment and four
behavioral syndromes (psychosis, overactivity, aggressive
behavior and depression) previously identified in this patient
group (Hope et al., 1997). We propose that cholinergic deficits
alone may not be sufficient to cause the marked changes
in cortical activity typical of AD. Cholinergic deficits may,
however, make neural circuits more susceptible to additional
neurochemical deficits and therefore, a compromised sero-
tonergic function, in combination with a cholinergic deficit,
may make an important contribution to the progression of the
illness.
2. Methods
2.1. Drugs used
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(mpairments in spatial memory and other behavioral tests,
dditional serotonergic blockade results in the appearance of
evere behavioral deficits. Consequently, it has been argued
hat serotonin plays a role in the maintenance of behavioral
apacities in the face of reduced cholinergic transmission
Dringenberg & Zalan, 1999). In AD, previous reports have
hown extensive serotonergic denervation (Chen, Alder, &
owen, 1996; Chen et al., 2000) although its clinical signifi-
ation has been only partially defined. Serotonin (5-HT) has
lso been involved in many psychobiological functions such
s aggression, depression, anxiety, or psychosis that are rele-
ant to BPSD (Chen et al., 1996; Lancot et al., 2001). In this
ontext, open label trials with selective serotonin reuptake
nhibitors (SSRIs) have been associated with improvements
n BPSD in a high proportion of patients (Parnetti, Amici,
anari, & Gallai, 2001). In addition, serotonergic pathways
re known to interact extensively with the cholinergic, nora-
renergic, GABAergic and dopaminergic systems and there-
ore, serotonergic therapies may be used to manipulate other
eurotransmitters systems to alleviate BPSD.
Different neurotransmitter systems, other than the seroton-
rgic and cholinergic systems have been implicated in AD.
eductions in noradrenergic markers have been reported in
D patients (Matthews et al., 2002). Data on the dopamin-
rgic system is not conclusive, and although some alter-
tions have been described in AD patients (Storga, Vrecko,
irkmayer, & Reinnegger, 1996) dopamine levels are not
ffected in other studies (Minger et al., 2000; Witte et al.,
999). There is also considerable evidence of alterations in
he glutamatergic system in AD and it has been described
hat reductions in glutamatergic markers correlate with theSuperpure H2O water (SpS, Romil), 0.22m filters
Millipore, UK). Acetylthiocholine iodide, sodium dode-
yl sulphate, 5,5′-dithio-bis(2-nitrobenzoic) acid and eserine
alicylate (Sigma-Aldrich Ltd, Germany), 14C-acetyl CoA
Amersham, UK), ecoscint TM (National Diagnostics, UK).
ll other chemicals were purchased from Panreac, USA.
.2. Patients and assessment of behavior
A total of 42 individuals were included in the study, 22
atients with clinical diagnosis of dementia and 20 elderly
ormal controls matched for age, gender, post-mortem de-
ay and brain pH (Table 1). Those patients with dementia
ere an autopsied subset of subjects included in a prospec-
ive study of behavioral changes in clinically diagnosed as
emented patients (Hope et al., 1997). Initially, all patients
ere living in community with a caregiver (usually spouse or
aughter) who could inform accurately about day-to-day be-
avior. More than one informant was assigned to institution-
lized patients when necessary. Drug histories were recorded
able 1
emographic features of patients
Control Alzheimer
ge (years) 74.75 ± 2.67 81.06 ± 1.60
ender (man/woman) 11/9 11/13
ost-mortem delay (h) 39.28 ± 5.40 48.63 ± 6.30
H 6.28 ± 0.16 6.44 ± 0.10
H, standard chemical symbol, negative log of hydrogen ion concentration
control n = 19–20, Alzheimer n = 20–22). Values are mean ± S.E.M.
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for all patients; 13 patients were taking major tranquilizers,
and 8 were taking minor tranquilizers. None of the patients
with AD received cholinomimetics. At entry to the study as-
sessment and diagnoses were made using (CAMDEX) (Roth
et al., 1986), DMS-III-R criteria (American Psychiatric
Association, 1987) and NINCDS-ADRA criteria (McKhann,
Drachman, & Folstein, 1984). Cognitive status was assessed
at 4 monthly intervals using the Mini-Mental State Examina-
tion (MMSE) (Folstein & Folstein, 1975). Decline in MMSE
was calculated as the difference between maximum scoring
and the scoring obtained last time the patient was examined
before death. Although the Mini-Mental State Examination
(MMSE) (Folstein & Folstein, 1975) presents some limita-
tions for the assessment of cognitive status in AD (Schmitt et
al., 2002) it is a practical test to be used serially and routinely.
Four behavioral and psychological syndromes were assessed
using the Present Behavioral Examination (PBE) (Hope &
Fairburn, 1992): depression, overactivity, psychosis and ag-
gressive behavior (Hope et al., 1997). Briefly, the PBE is
standardized, caregiver-based interview with high intra- and
interrater reliavility that covers in detail the observable be-
havior and mental state of the patient. Questions to elucidate
the caregiver answers were also included. Depression factor
was the sum of four components: apparent sadness, gloomy
thoughts, feeling like a failure and tearfulness. The overac-
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associated with terminal coma (Table 1). Brain pH is used as
an indication of tissue quality in post-mortem research, with
pH > 6.1 considered acceptable (Bahn et al., 2001; Lewis,
2002).
All subsequent analysis was performed blind to clinical
information.
2.4. Acetylcholine (ACh) and choline measurements
ACh and choline measurements were performed following
a method described by Takahashi, Ishimaru, Ikarashi, Kishi,
and Maruyama (1997) with minor modifications. Briefly, cor-
tical samples were homogenised in 20 volumes of 50 mM
HClO4 in Superpure H2O water. Homogenates were cen-
trifugated 10.000 g for 15 min. Supernants were filtrated by
centrifugation 2000 g for 2 min with 0.22m filters. Concen-
trations of ACh and its metabolite, choline, were determined
by high performance liquid chromatography (HPLC) with
electrochemical detection. All samples were assayed in du-
plicate and results were expressed per mg of wet tissue.
2.5. Acetylcholinesterase (AChE) determination
AChE assay was performed using a colorimetric method
reported by Wang et al. (1999) with minor modifications.
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civity factor consisted of the total of the highest ratings for
alking and trailing + checking. The psychosis factor was
he sum of scores for hallucinations, persecutory ideas and
nappropriate anxiety. Three different aspects of aggressive
ehavior were used in this analysis. These were physical ag-
ression, aggressive resistance and verbal aggression and the
ighest ratings were added together to give the aggressive be-
avior factor. Each component of the syndrome was scored
rom 0 to 2. A score of 0 meant that the behavior was absent.
score of 1 (mild) denoted that that particular type of behav-
or had occurred on up to half the days in the previous weeks.
rating of 2 (severe) meant that the behavior had occurred
n half of the days or more. This gives a maximum score
f 6 (or 8 for the depression factor). Factors were calculated
rom behavioral data for the last interview before death in
rder to correlate them with neurochemical data determined
ost-mortem.
.3. Tissue samples and neuropathology
Informed consent had been obtained from relatives before
or removal of brain tissue at death. At autopsy, brains were
emoved from 22 of the prospectively assessed cases with
linical diagnoses of dementia and from 20 elderly normal
ontrol cases. Blocks corresponding to frontal (Brodmann
rea 10, BA10) and temporal (Brodmann area 20, BA20)
ortex were removed and stored at −80 ◦C until processed.
ll 22 patients were found to meet CERAD criteria (Mirra
t al., 1991) for a diagnosis to AD. To partially mitigate the
ossible effects of cause of death on neurochemical deter-
inations, brain pH was measured as an index of acidosisrontal or temporal cortex was homogenised in 39 volumes
f 75 mM sodium phosphate buffer (pH 7.4). A mixture
f 2 ml containing acetylthiocholine iodide, 0.5 ml sodium
hosphate buffer (0.1 mM, pH 7.4) and 50l homogenate
as incubated for 8 min. The reaction was then terminated
y adding 0.5 ml 3% (w/v) sodium dodecyl sulphate followed
y 0.5 ml 0.2% (w/v) 5,5′-dithio-bis(2-nitrobenxoic) acid to
roduce the yellow anion of 5-thio-2-nitro-benzoic-acid. The
xtent of colour production was measured spectrophometri-
ally at 420 nm using Ultospec 3000 (Pharmacia Biotech). All
amples were assayed in triplicate. Results were expressed as
ercentage of control values.
.6. Cholinacetyltransferase (ChAT) activity
ChAT activity was performed using the method described
y Fonnum (1975) with minor modifications. Frontal or tem-
oral cortex was homogenised in 50 volumes of 0.87 mM
DTA contaning 0.1% Triton X-100 (pH 7.0). Duplicated
amples of 10l from homogenates were used in the assay.
he reaction mixture comprised the following: 87 nM EDTA
pH 7.4), 0.5 M NaH2PO4 (pH 7.4), 40 mM choline chlo-
ide 3 M NaCl, 2 nM eserine salicylate and 2 mM 14C-acetyl
oA. Samples were incubated at 37 ◦C for 30 min. Water was
sed as sample blanks The reaction was terminated by adding
00l of cold water. The acetylcholine product was separated
sing Kalignost solution: 0.5% cold sodium tetraphenyl-
orate in 15–85% acetonitrile–toluene. The supernatant was
hen transferred to scintillation cocktail (Ecoscint TM) and
adioactivity was measured. Results were expressed as per-
entage of control values.
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2.7. 5-HT and 5-HIAA measurements
5-HT and 5-HIAA concentrations were determined by
HPLC with electrochemical detection as previously de-
scribed by Perez-Otan˜o et al. (1991). Cortical samples were
homogenised in 20 vol of extraction mixture (0.4 M percloric
acid; 1 mM EDTA; 0.1% metabisulphitic acid and 50 ng/ml
DHBA as internal standard). Homogenates were centrifu-
gated at 32500 g for 20 min and 20l aliquots injected into
the HPLC were analyzed. All samples were assayed in du-
plicate and results were expressed per mg of wet tissue.
2.8. Statistical analysis
Data were analysed by SPSS for Windows, release
11.0. Student’s t-test was used in initial comparisons be-
tween control patients and patients with AD. The ef-
fects of demographic factors (age, post-mortem delay and
brain pH) on neurochemical variables were determined by
Pearson’s product–moment correlations. Intercorrelation of
neurochemical variables was also examined by Pearson’s
product–moment correlations. Spearman’s rank correlation
was also used for studies of the relationships between sever-
ity of dementia (MMSE score at last interview before death
or MMSE decline) and neurochemical measures. Multiple
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delay or brain pH and any of the neurochemical variables
studied in either the control or patients with dementia (P >
0.05) were found. However, they were included as covariates
in order to avoid age or post-mortem delay interferences in
subsequent analysis.
3.1. Neurochemical characterization of samples
All these results are summarised in Table 2.
3.1.1. Cholinergic system
Concentrations of both ACh and choline were significantly
reduced in AD patients compared to controls in both BA10
and BA20. As shown in Table 2, ACh reductions reached
55% in BA10 and 60% in BA20.
Similarly, AChE activity in frontal and temporal cortex
from AD patients was significantly lower than control pa-
tients. Reductions observed reached 30% in both cortical ar-
eas. ChAT activity was also reduced in BA10 (30%) and in
BA20 (35%) from AD patients when compared to control
values.
Individual concentrations of ACh were significantly corre-
lated with both choline and AChE in BA10 from AD patients
(ACh-choline n = 22; r = 0.545∗; P = 0.009; ACh-AChE n =
21; r = 0.507∗; P = 0.019). AChE and ChAT activities were
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Pegression analysis using “stepwise” method was used to in-
estigate possible relationships between neurochemical vari-
bles and the behavioral syndromes. As individual patients
ay show more than one behavioral syndrome, multiple-
egression indicates the strongest correlate (Minger et al.,
000).
. Results
Demographic details of subjects are shown in Table 1.
here were no significant differences in age, post-mortem
elay or brain pH between the control and AD groups. In ad-
ition, no significant correlations between age, post-mortem
able 2
eurochemical characterization of two cortical regions of patients with Alz
BA10
Control Alzheim
holinergic system
ACh 0.36± 0.04 0.15
Choline 377.55± 30.17 273.89
AChE 99.75± 2.80 71.65
ChAT 100.01± 9.82 30.91
erotonergic system
5-HT 52.95± 3.25 23.95
5-HIAA 201.10± 19.91 94.59
alues are mean ± S.E.M. ACh (acetylcholine) and choline are expressed
ransferase) are expressed as percentaje of control values and, 5-HT (seroton
A10 (Brodmann area 10) and BA20 (Brodmann area 20) from control (n =
∗∗ Significantly lower than control, Student’s t-test, P < 0.01.s disease and controls
BA20
Control Alzheimer
∗ 0.52± 0.08 0.22± 0.03∗∗
∗∗ 558.89± 29.36 257.55± 24.41∗
∗ 101.15± 2.09 66.70± 2.81∗∗
∗ 100.01± 7.34 35.00± 7.30∗∗
∗ 58.95± 4.09 28.26± 1.25∗∗
∗ 237.20± 20.02 94.70± 7.81∗∗
l/mg of wet tissue, AChE (acetylcholinesterase) and ChAT (cholinacetyl-
5-HIAA (5-hydroxyindolacetic acid) are expressed in pg/mg of wet tissue.
) and Alzheimer’s disease patients (n = 20–22).
lso significantly correlated in BA10 (n = 21; r = 0.507 ; P
0.019). In BA20, ACh levels were significantly correlated
ith and choline (n = 19; r = 0.481∗; P = 0.037) and AChE
ctivity (n = 19; r = 0.462∗; P < 0.045).
.1.2. Serotonergic system
Concentrations of both 5-HT and 5-HIAA were signifi-
antly reduced in BA10 and BA20 from AD patients. 5-HT
eductions reached 42% in BA10 and 52% in BA20, whereas
-HIAA levels were reduced in a 48% in BA10 and 55% in
A20 from AD patients.
5-HT and 5-HIAA levels were also correlated in BA10 (n
21; r = 0.478∗; P < 0.045) and BA20 (n = 21; r = 0.448∗;
< 0.042).
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3.2. Relationship between neurochemical variables with
the cognitive status
In AD patients mean MMSE score, and the MMSE de-
cline before death were 5 ± 1 and 10 ± 2, respectively.
Spearman’s rank correlation showed a statistically significant
positive correlation between final MMSE score and ChAT ac-
tivity both in BA10 (n = 20; r = 0.453∗; P = 0.045) and BA20
(n = 19; r = 0.639∗∗;P = 0.003) in AD patients. AChE activity
was also correlated with final MMSE scores in the frontal (n
= 20; r = 0.573∗∗; P = 0.008) as well as in temporal (n = 21;
r = 0.532∗; P = 0.013) cortex.
The ChAT/5-HT ratio showed significant correlations with
MMSE scores both in BA10 and BA20 (Fig. 1), and similar
results were found even though MMSE scores of 0 were re-
moved. When samples were separated by gender of the pa-
tients, the ratio between AChE and 5-HT levels in BA20 was
also correlated to MMSE decline in case of women (n = 12;
r = 0.534∗; P = 0.044). Moreover, women also showed a sig-
nificant correlation between ACh/5-HT and MMSE decline
(n = 11; r = 0.720∗; P = 0.019) in BA20.
3.3. Relationship between neurochemical variables with
behavioral syndromes
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Table 3
Step-wise multiple regression between neurochemical determinations and
behavioral and psychological syndromes in dementia
Aggression Overactivity Psychosis
AChE (BA10)
Adj r2 0.275∗
P 0.018
AChE (BA20)
Adj r2 0.251∗
P 0.023
ChAT (BA10)
Adj r2 0.231∗
P 0.029
ChAT (BA20)
Adj r2 0.321∗
P 0.012
5-HT (BA10)
Adj r2 0.220∗
P 0.038
5-HT (BA20)
Adj r2 0.221∗ (0.389∗)
P 0.028 (0.024)
AChE/5-HT (BA20)
Adj r2 0.236∗ (0.463∗)
P 0.026 (0.013)
Adj r2 (adjusted r2), P (statistical signification), AChE (acetyl-
cholinesterase), ChAT (cholineacetyltransferase), 5-HT (serotonin), BA10
(Brodmann area 10), BA20 (Brodmann area 20) (n = 20). Parenthesis data
corespond to women values (n = 10). Depression was not included as no
significant step-wise multiple regression was found between neurochemical
data and this behavioral factor.
∗ Significant stepwise multiple regression.
score showed a statistically significant negative correlation
in AD patients (n = 20, r = −0.707∗∗; P < 0.001).
The best predictor for 5-HT reductions in BA10 was over-
activity factor (Table 3). On the other hand, in BA20, 5-HT
levels and the ratio AChE to 5-HT levels were best predic-
tors for the psychotic factor. When separated by gender, these
correlations were due to women (Table 3).
4. Discussion
Reflecting the loss of cholinergic innervation, reductions
in AChE and ChAT have been reported in AD brains (Francis
et al., 1999; Giacobini, 2003). As expected, profound de-
pletions in all cholinergic markers measured (ACh, choline,
ChAT, AChE) were found both in frontal and temporal cortex
from AD patients in the present study. Important limitations
to consider in the study are the post-mortem delay and avail-
able clinical details. However, similar post-mortem delays to
those used in the present study have been described in the lit-
erature to measure biochemical markers (i.e. Lai et al., 2001).
Due to the labile nature of ACh in post-mortem tissue, data
on ACh levels have been taken cautiously.
Cholinergic degeneration in AD has been widely asso-
ciated with cognitive impairments in the illness (Terry &Final scores for BPSD assessed by PBE in AD patients
ere as follows: depression factor 3 ± 0.3; overactivity 3 ±
.4; psychosis 2 ± 0.3; aggressive behavior 5 ± 0.4.
Stepwise multiple regression indicated that the best pre-
ictor of lowered ChAT and AChE levels both in BA10 and
A20 was aggressive behavior scores among all four fac-
ors studied (Table 3). Aggressive behavior score and MMSE
ig. 1. Correlations between ChAT/5-HT ratio and MMSE from AD
Alzheimer’s disease) in BA10 (Brodmann area 10) and BA20 (Brodmann
rea 20) (n = 19–20). ChAT (cholinacetyltransferase), 5-HT (serotonin). ∗
r ∗∗ Significant Spearman’s rank correlations (P < 0.05 or P < 0.01).
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Buccafusco, 2003). In keeping with this argument, in our
study, ChAT and AChE levels were correlated to final MMSE
scores in AD. Supporting these data, AChE inhibitors such
as rivastigmine and donezepil have been shown to maintain
MMSE scores for up to 52 weeks in placebo-controlled study
(Tariot, 2001).
Regarding to the serotonergic system, and as previously
reported, a marked depletion in 5-HT and 5-HIAA levels
both in frontal and temporal cortex from AD patients was ob-
served. As well as pathology within synapses, considerable
loss of 5-HT in the cortex is likely due to loss of projections
from the raphe, as it has long been recognised that in AD
these nuclei are subject to neurofibrillary tangle formation.
We found no correlation between concentrations of 5-HT and
cognitive status. This was a somehow unexpected result as,
in keeping with the implication of the serotonergic system in
cognition, it has been described that 5-HT levels correlated
negatively with the rate of MMSE decline in the frontal cortex
(Lai et al., 1996). However, it has also been described that not
all patients with AD had depleted raphe neurons, indicating
that raphe neuron loss is not essential for cognitive decline
(Halliday et al., 1992). It could be argued that plasticity of the
serotonergic system enables surviving raphe neurons to suc-
cessfully take over the function of those cells that are lost until
an imbalance between the serotonergic–cholinergic systems
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cognitive impairment it could be argued that the relationship
between cholinergic deficits and aggressive behavior may be
because of a potential relationship between the behavioral
syndrome and cognitive impairment. Supporting this idea, we
have found a significant correlation between the final MMSE
score and aggressive behavior.
We found that the best predictor for 5-HT levels in frontal
cortex (BA10) was overactivity factor. On the other hand
the best predictor for 5-HT levels in temporal cortex (BA20)
was psychotic factor. Previous studies showed that psychosis
was associated with reductions in 5-HT in different brain
regions (Zubenko et al., 1991) and delusions and hallucina-
tions were observed in patients with lower cell counts in the
dorsal raphe nucleus (Forstl, Burns, Levy, & Cairns, 1994).
It is unclear why overactivity factor is correlated to 5-HT
levels in BA10 while correlations with the psychotic factor
appear in BA20, although possible explanations may include
functional specialization of the frontal and temporal cortex,
just like it has been already suggested for other BPSD in
AD patients (Mitchell, Colledge, Leonard, & Blair, 2002).
Psychotic manifestations in AD have been associated with
pathology in the temporal lobe (Forstl et al., 1994; Zubenko
et al., 1991) and there is also evidence that implicates tem-
poral areas in the production of hallucinations (Woodruff,
Wright, & Bullmore, 1997).
H
t
o
s
s
m
e
p
i
t
t
t
c
A
p
p
t
b
H
p
c
m
l
b
i
i
p
a
deads to cognitive impairments (Chen et al., 2000). In keeping
ith this idea, we have analyzed the ratio between choliner-
ic/serotonergic levels, e.g. a maintained ratio in a degenerat-
ng cholinergic system (as in AD) would be achieved through
decrease in the serotonergic input. We found that the quo-
ient between ChAT and 5-HT both in frontal and temporal
ortex was correlated to final MMSE scores. Moreover the
atios AChE/5-HT and ACh/5-HT were also correlated with
MSE decline at least in women. Taking into account that
-HT seems to act as an inhibitory neurotransmitter on cholin-
rgic neurons, decreases in the serotonergic tone would help
o maintain the cholinergic input in cholinoceptive deficient
arget areas (Garcia-Alloza et al., 2004). However, it is to
ote that a ratio between a pair of neurotransmitters may not
e the best approach, as the ratio may not change as they both
ecline, and therefore, these data should be considered with
aution.
Imperfect integration of memory and cognitive function
ay contribute to BPSD that most patients suffer in AD
Parnetti et al., 2001). Increasing evidence suggests that
holinergic deficiency in cortical regions might be linked to
PSD observed in AD patients (Minger et al., 2000). This
ontention is supported by the fact that anticholinergic drugs
xacerbate many of the behavioral abnormalities associated
o AD, and treatment with cholinergic compounds often im-
roves behavior. These observations provide the basis for the
holinergic hypothesis of the neuropsychiatric symptoms of
D (Cummings, 2000; Levy et al., 1999). In our study, in
eeping with findings from Minger et al. (2000), the best
redictor of low ChAT and AChE levels was agressive be-
avior. As ChAT and AChE decreases in AD also correlate toIn the temporal cortex (BA20) of women, the ratio 5-
T/AChE was also correlated to the psychotic factor and
herefore, women with AD may have a higher incidence
f delusions. It could be suggested that the profile of delu-
ions and hallucinations seen is different from that seen in
chizophrenia and the reason for these differences in AD
ay be linked to the cholinergic deficit. Indeed, the pres-
nce of psychotic symptoms in AD has been shown to be a
redictor of faster cognitive decline (Stern et al., 1994) and
t has been described the effectiveness of AChE inhibitors in
reating delusions or hallucinations (Morris et al., 1998).
The hypothesis of this study was that imbalance between
he cholinergic and serotonergic systems is related to cogni-
ive symptoms and BPSD in patients with AD. It seems in-
reasingly clear that the neuropsychiatric symptoms seen in
D are not simply a consequence of neurodegeneration, but
robably result from different or multiple neurotransmitter
athologic features, of which some patients are more at risk
han others. The major finding of this study is of relationships
etween neurochemical markers of both cholinergic and 5-
T systems and non-cognitive behavioral disturbance in
atients with dementia. In this work we have shown that corti-
al cholinergic AChE could be considered not only a putative
arker of accelerated cognitive decline in AD at the end of
ife, but it may be also implicated in BPSD such as aggressive
ehavior. Our results seem to support the use of cholinesterase
nhibitors in alleviating non-cognitive behavioral symptoms
n patients with AD. On the other hand 5-HT levels in tem-
oral cortex seem to be a good predictor of psychotic factor
ssociated to AD, although this implication might be me-
iated by cholinergic disruption. Traditional treatments for
448 M. Garcia-Alloza et al. / Neuropsychologia 43 (2005) 442–449
psychosis in AD are neuroleptics, strong dopamine D2 an-
tagonists, associated with extrapyramidal symptoms and that
may have anticholinergic side effects. Although atypical an-
tipsychotic drugs, such as risperidone (Defilippi & Crismon,
2000) represent alternative drugs for treating BPSD, it could
also be suggested that in pharmacotherapy of AD, attempts to
restore deficits of the transmitter systems might be directed
to the serotonergic system.
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